Patients Receiving a Kidney From a Non-Heart-Beating Donor Clinical Trial
Official title:
PROTECT: Prospective Trial on Erythropoietin in Clinical Transplantation
Randomized, double blind, placebo controlled, prospective trial investigating the effect of
erythropoietin in renal transplantation.
The investigators postulate that erythropoietin reduces the risk of delayed graft function.
Randomized, double blind, placebo controlled, prospective trial in patients, receiving a
kidney transplantation. Patients will be randomized to receive either Epoetin Beta
(Neorecormon; Roche) or placebo.
The primary endpoint will be delayed graft function. The anticipated duration of this trial
is 2 year and the target sample size is 60 patients per arm.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention